Solid Solution Compositions and Use in Chronic Inflammation

A solid solution pharmaceutical composition comprising:

• a) one or more propionic acid derived non-steroidal anti-inflammatory drugs (NSAIDs) in a concentration of about 100 mg/mL to about 750 mg/mL;
• b) one or more pharmaceutically-acceptable hard fats comprising one or more glycerolipids, the one or more glycerolipids comprising one or more triglycerides with one saturated or unsaturated fatty acid having a carbon length of C12-C24, one or more triglycerides with two saturated or unsaturated fatty acids each having a carbon length of C12-C24, or one or more triglycerides with three saturated or unsaturated fatty acids each having a carbon length of C12-C24, the one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the pharmaceutical composition;
• c) one or more pharmaceutically-acceptable liquid lipids comprising partially hydrolysed fats, the partially hydrolysed fats comprising a mixture of one or more monoglycerides, one or more diglycerides, and one or more triglycerides, the one or more pharmaceutically-acceptable liquid lipids in an amount of less than 45% by weight of the pharmaceutical composition,
• d) one or more liquid polyethylene glycol (PEG) polymers in an amount of about 5% to about 18% by weight of the pharmaceutical composition, and
• wherein the solid solution pharmaceutical composition is not a multi-phasic composition.